This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Regorafenib inhibits EphA2 phosphorylation and leads to liver damage via the ERK/MDM2/p53 axis
Nature Communications Open Access 13 May 2023
-
Baseline soluble MICA levels act as a predictive biomarker for the efficacy of regorafenib treatment in colorectal cancer
BMC Cancer Open Access 20 April 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Bruix, J. et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet http://dx.doi.org/10.1016/S0140-6736(16)32453-9 (2016).
Rights and permissions
About this article
Cite this article
Killock, D. Regorafenib — a new RESORCE in HCC. Nat Rev Clin Oncol 14, 70–71 (2017). https://doi.org/10.1038/nrclinonc.2016.214
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2016.214